RSVP: Charles Payne’s Cash Flow Workshop

Are you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.

Jeff Goater Biography and Net Worth

Director of Surface Oncology

Jeff Goater served as chief executive officer of Surface Oncology from February 2018 to March 2021. Previously, he served as Surface’s chief business officer from February 2017 to February 2018. Prior to Surface, he served as chief financial officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he oversaw business development, business operations, finance, investor and public relations, and played a leading role in the establishment of Voyager’s strategic partnership with Sanofi Genzyme, as well as its initial public offering. Previously, Jeff spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist and holds master’s degrees in microbiology/immunology, pathology and business administration from the University of Rochester. In addition to his role at Surface, Jeff also serves on the board of Vaccinex, Inc and LogicBio Therapeutics.

What is Jeff Goater's net worth?: The estimated net worth of Jeff Goater is at least $494,340.00 as of June 10th, 2021. Mr. Goater owns 462,000 shares of Surface Oncology stock worth more than $494,340 as of May 8th. This net worth estimate does not reflect any other assets that Mr. Goater may own. Learn More about Jeff Goater's net worth.
How do I contact Jeff Goater?: The corporate mailing address for Mr. Goater and other Surface Oncology executives is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. Surface Oncology can also be reached via phone at (617) 714-4096 and via email at [email protected]. Learn More on Jeff Goater's contact information.
Has Jeff Goater been buying or selling shares of Surface Oncology?: Jeff Goater has not been actively trading shares of Surface Oncology during the past quarter. Most recently, Jeff Goater sold 234,727 shares of the business's stock in a transaction on Thursday, June 10th. The shares were sold at an average price of $7.66, for a transaction totalling $1,798,008.82. Following the completion of the sale, the director now directly owns 462,000 shares of the company's stock, valued at $3,538,920. Learn More on Jeff Goater's trading history.
Are insiders buying or selling shares of Surface Oncology?: During the last twelve months, insiders at the sold shares 3 times. They sold a total of 30,048 shares worth more than $28,245.12. The most recent insider tranaction occured on August, 1st when insider Chandra Adams sold 3,901 shares worth more than $3,666.94. Insiders at Surface Oncology own 12.0% of the company. Learn More about insider trades at Surface Oncology.
Information on this page was last updated on 8/1/2023.

Jeff Goater Insider Trading History at Surface Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/10/2021	Sell	234,727	$7.66	$1,798,008.82	462,000
2/8/2021	Sell	2,500	$12.50	$31,250.00	264,500
2/1/2021	Sell	2,500	$10.69	$26,725.00	264,500
1/19/2021	Sell	5,000	$13.00	$65,000.00	267,000
2/5/2020	Buy	5,000	$3.05	$15,250.00

Jeff Goater Buying and Selling Activity at Surface Oncology

Surface Oncology Company Overview

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.

Today's Range

Now: $1.07

$1.01

$1.09

50 Day Range

MA: $1.01

$0.88

$1.08

2 Week Range

Now: $1.07

$0.56

$1.43

Volume

1,510,100 shs

Average Volume

430,375 shs

Market Capitalization

$65.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

The Gold Grab of the Century

From Colonial Metals | Ad

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.